Zomedica Achieves Record Revenue and Steady Growth in 2023

Zomedica Pharmaceuticals (ZOM) has released an update.

Zomedica Pharmaceuticals has announced a record-breaking revenue of $7.3 million for Q4 and $25.2 million for the full year of 2023, marking a significant 33% annual growth. The company attributes this success to the early adoption of new products in its Diagnostics segment and solid performance in Therapeutic Devices. Zomedica, maintaining a strong 69% gross margin and a robust liquidity position of $100.5 million, is poised for continued growth in 2024.

For further insights into ZOM stock, check out TipRanks’ Stock Analysis page.